MYC is one of the most common and well-studied pan-cancer oncogenes, while FAM46C is now becoming a well-established pan-cancer tumour suppressor, making this anti-correlation really attractive and exploitable for future therapy implementation. The gene discussed is MYC; the disease is neoplasm.